Definitive Healthcare (NASDAQ:DH) Releases Q2 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its second quarter earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $0.08-$0.09 for the period, compared to the consensus estimate of $0.09. The company issued revenue guidance of $62.0-$63.5 million, compared to the consensus revenue estimate of $65.19 million. Definitive Healthcare also updated its FY24 guidance to $0.36-$0.38 EPS.

Definitive Healthcare Stock Down 3.4 %

Shares of NASDAQ:DH traded down $0.18 during trading on Thursday, hitting $5.17. 3,323,524 shares of the company were exchanged, compared to its average volume of 643,916. The stock has a market cap of $608.97 million, a price-to-earnings ratio of -2.86, a P/E/G ratio of 6.12 and a beta of 1.41. Definitive Healthcare has a fifty-two week low of $4.38 and a fifty-two week high of $12.45. The firm has a fifty day moving average price of $7.70 and a two-hundred day moving average price of $8.29. The company has a current ratio of 2.31, a quick ratio of 2.31 and a debt-to-equity ratio of 0.20.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.02). Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. The firm had revenue of $65.93 million for the quarter, compared to analyst estimates of $66.01 million. As a group, research analysts anticipate that Definitive Healthcare will post 0.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on DH. Morgan Stanley lowered shares of Definitive Healthcare from an overweight rating to an equal weight rating and lowered their price target for the stock from $11.50 to $9.00 in a research report on Wednesday. Barclays cut their target price on shares of Definitive Healthcare from $11.00 to $7.00 and set an equal weight rating on the stock in a research report on Thursday. Deutsche Bank Aktiengesellschaft cut their target price on Definitive Healthcare from $10.00 to $7.00 and set a hold rating on the stock in a report on Thursday. Stifel Nicolaus decreased their price target on Definitive Healthcare from $11.00 to $9.50 and set a buy rating for the company in a research note on Wednesday. Finally, Needham & Company LLC restated a hold rating on shares of Definitive Healthcare in a report on Wednesday. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Hold and a consensus target price of $9.94.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.